公开(公告)号：WO2012096975A3

公开(公告)日：2014-04-24

申请号：PCT/US2012020802

申请日：2012-01-10

Applicant: UNIV LELAND STANFORD JUNIOR ,  ALIZADEH ARASH ASH ,  DENNEY DAN ,  LEVY RONALD

Inventor： ALIZADEH ARASH ASH ,  DENNEY DAN ,  LEVY RONALD

IPC: A61K39/395

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N33/57426 ,  G01N33/686 ,  G01N2800/52

Abstract: Predictive biomarkers identify those patients suffering from immunoglobulin positive (lg+) B lineage malignancies that are responsive to active immunotherapy, where the active immunotherapy comprises vaccination with a tumor-specific idiotype-immunogen. It is shown herein that patient responsiveness to the idiotype-immunogen is dependent upon the sequence of the immunogen, where an immunogen having a low number of tyrosine residues in the CDR1 (herein termed CDR1 -Y10) regions of one or both of the immunogen heavy and light chains is predictive of a positive anti-tumor response, while a high number of CDR1 tyrosine residues (herein termed CDR1 -Yhi) is predictive of a low anti tumor response.

Abstract translation: 预测性生物标志物识别患有对主动免疫治疗有反应的免疫球蛋白阳性（IgG）B系恶性肿瘤的患者，其中主动免疫治疗包括用肿瘤特异性独特型免疫原接种疫苗。 这里显示了患者对独特型免疫原的反应性取决于免疫原的序列，其中免疫原重量的一个或两个的CDR1（这里称为CDR1-Y10）区域中具有低数量酪氨酸残基的免疫原 轻链可预测阳性的抗肿瘤反应，而大量的CDR1酪氨酸残基（这里称为CDR1-Yhi）预示着低的抗肿瘤反应。

公开(公告)号：WO2005067980A3

公开(公告)日：2006-10-26

申请号：PCT/US2005000816

申请日：2005-01-10

Applicant: POINTILLISTE INC ,  AULT-RICHE DANA ,  LEVY RONALD

Inventor： AULT-RICHE DANA ,  LEVY RONALD

IPC: A61K39/395 ,  A61K47/48 ,  C07K16/28 ,  C07K16/42

CPC classification number: B82Y5/00 ,  A61K39/39566 ,  A61K47/665 ,  A61K47/6897 ,  A61K2039/505 ,  C07K16/2896 ,  C07K16/4241 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2319/30 ,  A61K2300/00

Abstract: Therapeutic complexes and components of therapeutic complexes are provided herein. Also provided are methods of preparing therapeutic complexes and methods of administering therapeutic complexes.

Abstract translation: 本文提供治疗复合物和治疗复合物的组分。 还提供了制备治疗复合物的方法和施用治疗复合物的方法。

公开(公告)号：WO2005067980A2

公开(公告)日：2005-07-28

申请号：PCT/US2005/000816

申请日：2005-01-10

Applicant: POINTILLISTE, INC. ,  AULT-RICHE, Dana ,  LEVY, Ronald

Inventor： AULT-RICHE, Dana ,  LEVY, Ronald

IPC: A61K47/48

CPC classification number: B82Y5/00 ,  A61K39/39566 ,  A61K47/665 ,  A61K47/6897 ,  A61K2039/505 ,  C07K16/2896 ,  C07K16/4241 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2319/30 ,  A61K2300/00

Abstract: Therapeutic complexes and components of therapeutic complexes are provided herein. Also provided are methods of preparing therapeutic complexes and methods of administering therapeutic complexes.

Abstract translation: 本文提供治疗复合物和治疗复合物的组分。 还提供了制备治疗复合物的方法和施用治疗复合物的方法。

公开(公告)号：WO1994008601A1

公开(公告)日：1994-04-28

申请号：PCT/US1993009895

申请日：1993-10-14

Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD ... ,  LEVY, Ronald ,  TAO, Mi-Hua

Inventor： THE BOARD OF TRUSTEES OF THE LELAND STANFORD ...

IPC: A61K37/00

CPC classification number: C07K16/00 ,  A61K39/00 ,  A61K2039/505 ,  C07K14/52 ,  C07K16/30 ,  C07K16/4208 ,  C07K2317/73 ,  C07K2319/00 ,  C07K2319/30

Abstract: Immunocomplexes which consist essentially of a B cell lymphoma tumor-associated antigen or a fragment thereof containing an epitope characteristic of the tumor and an immune-enhancing cytokine such as GM-CSF, IL-2 or IL-4 elicit immune responses which are protective with respect to tumor proliferation. Antibodies immunoreactive with these immunocomplexes are also useful as passive vaccines and as analytical tools.

Abstract translation: 基本上由B细胞淋巴瘤肿瘤相关抗原或其含有肿瘤特征性表位的片段和免疫增强细胞因子如GM-CSF，IL-2或IL-4组成的免疫复合物引起免疫应答，其具有保护性 尊重肿瘤扩散。 与这些免疫复合物免疫反应的抗体也可用作被动疫苗和分析工具。

公开(公告)号：WO2011071871A1

公开(公告)日：2011-06-16

申请号：PCT/US2010/059221

申请日：2010-12-07

Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY ,  KOHRT, Holbrook ,  HOUOT, Roch ,  LEVY, Ronald ,  ALIZADEH, Arash Ash ,  GOLDSTEIN, Matthew J. ,  TORCHIA, James

Inventor： KOHRT, Holbrook ,  HOUOT, Roch ,  LEVY, Ronald ,  ALIZADEH, Arash Ash ,  GOLDSTEIN, Matthew J. ,  TORCHIA, James

IPC: A61K39/395

CPC classification number: C07K16/2896 ,  A61K2039/507 ,  C07K16/2863 ,  C07K16/2878 ,  C07K16/2887 ,  C07K16/2893 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/3046 ,  C07K16/3069 ,  C07K16/32 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/75 ,  G01N33/57492 ,  G01N2333/70578

Abstract: Methods of enhancing the efficacy of antibody-directed cellular cytotoxicity (ADCC) for therapy directed to killing of tumor cells are disclosed. Cancer specific cell surface antigens are bound by monoclonal antibodies, thereby stimulating a cytotoxic T cell response characterized by an upregulation of cell surface expression of costimulatory molecules on the T cell. The ADCC response is augmented by the subsequent administration of a second antibody that is an agonist of the costimulatory molecule.

Abstract translation: 公开了增强针对杀死肿瘤细胞的治疗的抗体定向细胞毒性（ADCC）功效的方法。 癌症特异性细胞表面抗原由单克隆抗体结合，从而刺激特征在于T细胞上共刺激分子的细胞表面表达上调的细胞毒性T细胞应答。 通过随后施用作为共刺激分子的激动剂的第二抗体来增强ADCC应答。

公开(公告)号：WO2008002663A2

公开(公告)日：2008-01-03

申请号：PCT/US2007/015220

申请日：2007-06-28

Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY ,  FUNDAMENTAL APPLIED BIOLOGY, INC. ,  SWARTZ, James Robert ,  YANG, Junhao ,  VOLOSHIN, Alexei M. ,  LEVY, Ronald ,  KANTER, Gregg ,  YIN, Gang ,  FONSTAD, Diego ,  KROCAK, James ,  LEVY, Shoshana

Inventor： SWARTZ, James Robert ,  YANG, Junhao ,  VOLOSHIN, Alexei M. ,  LEVY, Ronald ,  KANTER, Gregg ,  YIN, Gang ,  FONSTAD, Diego ,  KROCAK, James ,  LEVY, Shoshana

IPC: A61K39/145

CPC classification number: C07K14/005 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/145 ,  A61K39/385 ,  A61K2039/55522 ,  A61K2039/6068 ,  C07K16/00 ,  C07K2317/622 ,  C07K2319/21 ,  C07K2319/40 ,  C12N2760/16022 ,  C12N2760/16034 ,  C12N2760/16134

Abstract: Bacterial immunity proteins are utilized to increase immune response to an antigen of interest.

Abstract translation: 利用细菌免疫蛋白来增加对感兴趣抗原的免疫应答。

公开(公告)号：WO2008002663A3

公开(公告)日：2008-09-18

申请号：PCT/US2007015220

申请日：2007-06-28

Applicant: UNIV LELAND STANFORD JUNIOR ,  FUNDAMENTAL APPLIED BIOLOGY IN ,  SWARTZ JAMES ROBERT ,  YANG JUNHAO ,  VOLOSHIN ALEXEI M ,  LEVY RONALD ,  KANTER GREGG ,  YIN GANG ,  FONSTAD DIEGO ,  KROCAK JAMES ,  LEVY SHOSHANA

Inventor： SWARTZ JAMES ROBERT ,  YANG JUNHAO ,  VOLOSHIN ALEXEI M ,  LEVY RONALD ,  KANTER GREGG ,  YIN GANG ,  FONSTAD DIEGO ,  KROCAK JAMES ,  LEVY SHOSHANA

IPC: C12N1/21 ,  A61K35/00 ,  A61K38/00

CPC classification number: C07K14/005 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/145 ,  A61K39/385 ,  A61K2039/55522 ,  A61K2039/6068 ,  C07K16/00 ,  C07K2317/622 ,  C07K2319/21 ,  C07K2319/40 ,  C12N2760/16022 ,  C12N2760/16034 ,  C12N2760/16134

Abstract: Bacterial immunity proteins are utilized to increase immune response to an antigen of interest.

Abstract translation: 利用细菌免疫蛋白来增加对感兴趣的抗原的免疫应答。

公开(公告)号：WO2018022930A1

公开(公告)日：2018-02-01

申请号：PCT/US2017/044238

申请日：2017-07-27

Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY ,  LEVY, Ronald ,  HAABETH, Ole, Audun Werner ,  BENNER, Nancy ,  NEAR, Katherine

Inventor： LEVY, Ronald ,  HAABETH, Ole, Audun Werner ,  BENNER, Nancy ,  NEAR, Katherine ,  WAYMOUTH, Robert, M. ,  WENDER, Paul ,  VARGAS, Jessica, R. ,  BLAKE, Tim, R. ,  MCKINLAY, Colin

IPC: A61K31/496 ,  A61K47/26

Abstract: There are provided herein, inter alia, complexes, compositions and methods for the delivery of therapeutic, diagnostic and imaging agents, including nucleic acid, into a cell. The complexes, compositions and methods may facilitate complexation, protection, delivery and release of oligonucleotides and polyanionic cargos into target cells, tissues, and organs both in vitro and in vivo.

Abstract translation: 本文提供了用于将治疗剂，诊断剂和显像剂（包括核酸）递送到细胞中的复合物，组合物和方法。 复合物，组合物和方法可促进寡核苷酸和聚阴离子货物在体外和体内在靶细胞，组织和器官中的络合，保护，递送和释放。

公开(公告)号：WO2012096975A2

公开(公告)日：2012-07-19

申请号：PCT/US2012/020802

申请日：2012-01-10

Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY ,  ALIZADEH, Arash Ash ,  DENNEY, Dan ,  LEVY, Ronald

Inventor： ALIZADEH, Arash Ash ,  DENNEY, Dan ,  LEVY, Ronald

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N33/57426 ,  G01N33/686 ,  G01N2800/52

Abstract: Predictive biomarkers identify those patients suffering from immunoglobulin positive (lg + ) B lineage malignancies that are responsive to active immunotherapy, where the active immunotherapy comprises vaccination with a tumor-specific idiotype-immunogen. It is shown herein that patient responsiveness to the idiotype-immunogen is dependent upon the sequence of the immunogen, where an immunogen having a low number of tyrosine residues in the CDR1 (herein termed CDR1 -Y 10 ) regions of one or both of the immunogen heavy and light chains is predictive of a positive anti-tumor response, while a high number of CDR1 tyrosine residues (herein termed CDR1 -Y hi ) is predictive of a low anti tumor response.

Abstract translation: 预测性生物标志物识别患有对主动免疫治疗有反应的免疫球蛋白阳性（IgG）B系恶性肿瘤的患者，其中主动免疫治疗包括用肿瘤特异性独特型免疫原接种疫苗。 这里显示了患者对独特型免疫原的反应性取决于免疫原的序列，其中免疫原重量的一个或两个的CDR1（这里称为CDR1-Y10）区域中具有低数量酪氨酸残基的免疫原 轻链可预测阳性的抗肿瘤反应，而大量的CDR1酪氨酸残基（这里称为CDR1-Yhi）预示着低的抗肿瘤反应。

公开(公告)号：WO2005038057A1

公开(公告)日：2005-04-28

申请号：PCT/US2004/034874

申请日：2004-10-11

Applicant: APPLERA CORPORATION ,  LEVY, Ronald ,  WECHSER, Mark A. ,  LOSSOS, Izidore S. ,  TIBSHIRANI, Robert J. ,  ALIZADEH, Ash A. ,  BOTSTEIN, David

Inventor： LEVY, Ronald ,  WECHSER, Mark A. ,  LOSSOS, Izidore S. ,  TIBSHIRANI, Robert J. ,  ALIZADEH, Ash A. ,  BOTSTEIN, David

IPC: C12Q1/68

CPC classification number: G01N33/57426 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/16

Abstract: Methods and kits for classifying patients having diffuse large B-cell lymphoma (DLBCL) based upon expression of a plurality of genes are disclosed. Real-time quantitative RT-PCR can be used to measure expression values. Correlating expression values of the plurality of genes in a tumor sample from the patient to reference expression values obtained from DLBCL patients can stratify patients in the classification groups. The methods and kits can be used to predict overall patient survival.

Abstract translation: 公开了基于多个基因的表达来分类具有弥漫性大B细胞淋巴瘤（DLBCL）的患者的方法和试剂盒。 实时定量RT-PCR可用于测量表达值。 将来自患者的肿瘤样品中的多个基因的表达值与从DLBCL患者获得的参照表达值相关联可以对分类组中的患者进行分层。 方法和试剂盒可用于预测总体患者生存。